Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 3 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T
Eur Heart J.2016 Jun 1;37(21):1671-80
CARDIONCOLOGY.ORG ABSTRACT:
This study tests the hypothesis that concomitant therapy with the angiotensin receptor blocker candesartan or the β-blocker metoprolol will alleviate the decline in left ventricular ejection fraction (LVEF) associated with adjuvant, anthracycline-containing regimens with or without trastuzumab and radiation.
Results indicate thatIn patients treated for early breast cancer with adjuvant anthracycline-containing regimens with or without trastuzumab and radiation, concomitant treatment with candesartan provides protection against early decline in global left ventricular function.
© All Rights Reserved
fonte foto: https://universityhealthnews.com/daily/heart-health/what-is-congestive-heart-failure/